Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YTB323 in Relapsing Multiple Sclerosis
NCT06617793Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2025
- Primary completion
- Aug 2030
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 6
01
Overview
Phase 2, open-label trial of rapcabtagene autoleucel in multiple sclerosis (MS) (4 cohorts), sponsored by Novartis. Primary endpoint: Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Feb 2025; status: active, not recruiting.
02
Drugs
rapcabtagene autoleucel
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06617793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06617793.